Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice

Journal of Clinical Investigation

Volumn 122, Issue 5, 2012, Pages 1688-1699

  Zhang, Yuan ^a   Breevoort, Sarah R ^b   Angdisen, Jerry ^b   Fu, Mingui ^a,e   Schmidt, Daniel R ^a   Holmstrom, Sam R ^a   Kliewer, Steven A ^a,c   Mangelsdorf, David J ^a,c   Schulman, Ira G ^b,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GENE TARGETING; HOMEOSTASIS; LIPID METABOLISM; LIVER CELL; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHOLESTEROL; FECES; FEMALE; GENE KNOCKOUT TECHNIQUES; HOMEOSTASIS; HYDROCARBONS, FLUORINATED; LIPID METABOLISM; LIPOPROTEINS; LIVER; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGAN SPECIFICITY; ORPHAN NUCLEAR RECEPTORS; PARTICLE SIZE; SULFONAMIDES; TRIGLYCERIDES;

EID: 84860548049     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI59817     Document Type: Article

References (68)

1. Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation. 1989;80(4):1070-1078. (Pubitemid 19261655)
2. Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(8):1513-1518.
3. Chen W, Chen G, Head DL, Mangelsdorf DJ, Russell DW. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 2007;5(1):73-79. (Pubitemid 44933109)
4. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signaling pathway mediated by the nuclear receptor LXRα. Nature. 1996;383(6602):728-731. (Pubitemid 26360651)
5. Edmondson AC, et al. Dense genotyping of candidate gene loci identifies variants associated with high-density lipoprotein cholesterol. Circ Cardiovasc Genet. 2011;4(2):145-155.
6. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707-713.
7. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 2001;42(8):1173-1179. (Pubitemid 32744239)
8. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;(50 suppl):S189-S194.
9. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7(5):365-375. (Pubitemid 351598023)
10. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104(4):503-516. (Pubitemid 32201946)
11. Schulman IG, Heyman RA. LXR as a therapeutic target for atherosclerosis. In: Packard CJ, Rader DJ, eds. Lipids and Atherosclerosis. London, United Kingdom: Taylor & Francis; 2006:93-100.
12. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem. 2002;277(21):18793-18800. (Pubitemid 34952438)
13. Yu L, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem. 2003;278(18):15565- 15570. (Pubitemid 36799664)
14. Berge KE, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771- 1775. (Pubitemid 32004809)
15. Bischoff ED, et al. Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice. J Lipid Res. 2010;51(5):900-906.
16. Joseph SB, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99(11):7604-7609. (Pubitemid 34568738)
17. Levin N, et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol. 2005;25(1):135-142. (Pubitemid 40054266)
18. Terasaka N, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 2003;536(1-3):6-11. (Pubitemid 36206397)
19. Repa JJ, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14(22):2819-2830.
20. Schultz JR, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14(22):2831-2838.
21. Joseph SB, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem. 2002;277(13):11019-11025. (Pubitemid 34952859)
22. Peet DJ, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRá. Cell. 1998;93(5):693-704. (Pubitemid 28257577)
23. Groot PH, et al. Synthetic LXR agonists increase LDL in CETP species. J Lipid Res. 2005;46(10):2182-2191. (Pubitemid 41377470)
24. Quinet EM, et al. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting. Mol Pharmacol. 2006;70(4):1340-1349. (Pubitemid 44435986)
25. Svensson S, et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligandbinding domains in a fully agonistic conformation. EMBO J. 2003;22(18):4625-4633. (Pubitemid 37162899)
26. Williams S, et al. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J Biol Chem. 2003;278(29):27138-27143. (Pubitemid 36876869)
27. Bradley MN, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest. 2007;117(8):2337-2346. (Pubitemid 47219578)
28. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(7):1169-1177. (Pubitemid 36873813)
29. Motoshima K, Noguchi-Yachide T, Sugita K, Hashimoto Y, Ishikawa M. Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists. Bioorg Med Chem. 2009;17(14):5001-5014.
30. Houck KA, et al. T0901317 is a dual LXR/FXR agonist. Mol Genet Metab. 2004;83(1-2):184-187. (Pubitemid 39311292)
31. Kumar N, et al. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)- N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl] -benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha/gamma inverse agonist. Mol Pharmacol. 2010;77(2):228-236.
32. Mitro N, Vargas L, Romeo R, Koder A, Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 2007;581(9):1721-1726. (Pubitemid 46602262)
33. Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, Redinbo MR. Crystal structure of the PXRT1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem. 2007;15(5):2156-2166. (Pubitemid 46176620)
34. Grefhorst A, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002;277(37):34182-34190.
35. Zhang Y, Repa JJ, Gauthier K, Mangelsdorf DJ. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J Biol Chem. 2001;276(46):43018-43024.
36. Plosch T, et al. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem. 2002;277(37):33870-33877.
37. Yu L, et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem. 2005;280(10):8742-8747. (Pubitemid 40409561)
38. Kruit JK, et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology. 2005;128(1):147-156. (Pubitemid 40039966)
39. van der Veen JN, et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem. 2009;284(29):19211-19219.
40. Temel RE, et al. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab. 2010;12(1):96-102.
41. Lehmann JM, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997;272(6):3137-3140. (Pubitemid 27066798)
42. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-174. (Pubitemid 36930444)
43. Wang DQ, Lammert F, Cohen DE, Paigen B, Carey MC. Cholic acid aids absorption, biliary secretion, and phase transitions of cholesterol in murine cholelithogenesis. Am J Physiol. 1999;276(3 pt 1):G751-G760. (Pubitemid 29157442)
44. Wang DQ, Tazuma S. Effect of beta-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res. 2002;43(11):1960-1968. (Pubitemid 35315814)
45. Brunham LR, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116(4):1052-1062.
46. Timmins JM, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115(5):1333-1342. (Pubitemid 40629053)
47. Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ Res. 2006;99(7):672-674. (Pubitemid 44498301)
48. Lo Sasso G, et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010;12(2):187-193.
49. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26(4):847-870. (Pubitemid 44716510)
50. Hammad SM, Powell-Braxton L, Otvos JD, Eldridge L, Won W, Lyons TJ. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism. 2003;52(7):916-921. (Pubitemid 36949556)
51. Naik SU, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113(1):90-97. (Pubitemid 43958493)
52. Wang X, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117(8):2216-2224. (Pubitemid 47219566)
53. Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology. 2011;140(3):1043-1051.
54. Singaraja RR, et al. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation. 2006;114(12):1301-1309. (Pubitemid 44402056)
55. Tangirala RK, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A. 2002;99(18):11896- 11901. (Pubitemid 34994495)
56. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(2):160-167. (Pubitemid 36231923)
57. Erbay E, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009;15(12):1383-1391.
58. Feig JE, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest. 2010;120(12):4415-4424.
59. Murphy AJ, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest. 2011;121(10):4138-4149.
60. Yvan-Charvet L, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328(5986):1689-1693.
61. Yasuda T, Grillot D, Billheimer JT, Briand F, Delerive P, Huet S, Rader DJ. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 2010;30(4):781-786.
62. Kalaany NY, et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab. 2005;1(4):231-244. (Pubitemid 43960607)
63. Turley SD, Daggy BP, Dietschy JM. Psyllium augments the cholesterol-lowering action of cholestyramine in hamsters by enhancing sterol loss from the liver. Gastroenterology. 1994;107(2):444-452. (Pubitemid 24233319)
64. Turley SD, Daggy BP, Dietschy JM. Effect of feeding psyllium and cholestyramine in combination on low density lipoprotein metabolism and fecal bile acid excretion in hamsters with dietary-induced hypercholesterolemia. J Cardiovasc Pharmacol. 1996;27(1):71-79. (Pubitemid 26010642)
65. Yu L, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest. 2002;110(5):671-680. (Pubitemid 34988791)
66. Lee YK, et al. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol Endocrinol. 2008;22(6):1345-1356.
67. Bookout AL, Mangelsdorf DJ. Quantitative realtime PCR protocol for analysis of nuclear receptor signaling pathways. Nucl Recept Signal. 2003;1:e012.
68. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res. 1995;36(11):2320-2328.